Viatris VTRS Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Developed Markets Segment | $2.03B-10.3% | $2.26B-0.3% | $2.27B+6.4% | $2.13B+12.2% | $1.9B-11.9% | |
| Emerging Markets Segment | $537.4M-5.0% | $565.8M-1.0% | $571.8M+2.7% | $556.9M+6.5% | $523.1M+1.8% | |
| Greater China | $680.1M+18.7% | $572.9M-6.9% | $615.2M+4.5% | $588.9M+6.0% | $555.5M+6.4% | |
| Japan, Australia and New Zealand Segment | $273.5M-10.8% | $306.6M-0.2% | $307.3M+0.2% | $306.7M+10.7% | $277.1M-17.6% | |
| Net Sales by Product | ||||||
| Brands | $2.33B-0.6% | $2.35B-3.7% | $2.44B+6.7% | $2.28B+7.9% | $2.12B-2.3% | |
| Celebrex ® | $67.1M+1.4% | $66.2M-9.7% | $73.3M+4.7% | $70M+10.4% | $63.4M-5.5% | |
| Creon ® | $97.4M-1.5% | $98.9M+6.2% | $93.1M+1.9% | $91.4M+10.9% | $82.4M-8.8% | |
| Dymista ® | $37.3M-3.4% | $38.6M+14.2% | $33.8M-30.2% | $48.4M+13.1% | $42.8M+3.6% | |
| Effexor ® | $62M-9.0% | $68.1M+1.3% | $67.2M+6.5% | $63.1M+6.4% | $59.3M-8.1% | |
| EpiPen® Auto-Injectors | $101.1M+28.0% | $79M-49.7% | $157.2M+14.9% | $136.8M+41.5% | $96.7M+32.3% | |
| Generics | $1.18B-12.5% | $1.34B+2.6% | $1.31B+2.0% | $1.28B+14.0% | $1.13B-16.5% | |
| Lipitor | $462M+22.4% | $377.3M-4.7% | $396.1M+2.1% | $387.9M0.0% | $388M+9.0% | |
| Lyrica ® | $120.6M+0.7% | $119.8M-5.3% | $126.5M-1.2% | $128.1M+13.8% | $112.6M-11.3% | |
| Norvasc | $210M+19.9% | $175.2M-2.5% | $179.7M-1.6% | $182.7M+6.0% | $172.3M+3.7% | |
| Viagra ® | $95M-8.8% | $104.2M-1.0% | $105.2M+4.9% | $100.3M+1.8% | $98.5M+11.2% | |
| Xalabrands | $39.2M-6.7% | $42M+8.8% | $38.6M-5.2% | $40.7M+9.7% | $37.1M0.0% | |
| Xanax ® | $34.8M-11.9% | $39.5M+15.5% | $34.2M+0.9% | $33.9M+5.0% | $32.3M-11.5% | |
| Yupelri ® | $62.5M-11.5% | $70.6M-1.1% | $71.4M+7.2% | $66.6M+14.2% | $58.3M-12.5% | |
| Zoloft ® | $72.6M+8.7% | $66.8M0.0% | $66.8M+9.3% | $61.1M+1.5% | $60.2M+3.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Viatris break its business down?
- Viatris (VTRS) reports net sales by business across 4 parts — Developed Markets Segment, Emerging Markets Segment, Greater China and Japan, Australia and New Zealand Segment. Each is extracted from the segment footnotes and tracked over time.
- Where does Viatris's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Viatris's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
